Tue, Jan 27, 2015, 8:57 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

btimnextmicrosoft 80 posts  |  Last Activity: 8 hours ago Member since: Oct 15, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • btimnextmicrosoft btimnextmicrosoft Dec 26, 2014 1:58 PM Flag

    Agree, GE tip of the iceberg

  • Reply to

    BTX pop has begun

    by baltbearfinance Dec 24, 2014 1:32 PM
    btimnextmicrosoft btimnextmicrosoft Dec 24, 2014 3:50 PM Flag

    Cancer diagnostic products hit the market end of 2015, I'd think we are looking at a triple by then.

  • btimnextmicrosoft btimnextmicrosoft Dec 24, 2014 3:48 PM Flag

    Sorry buddy, not getting my shares, happy holiday.....'ignored'

  • Reply to

    New PR

    by garyd288 Dec 18, 2014 8:51 AM
    btimnextmicrosoft btimnextmicrosoft Dec 18, 2014 5:50 PM Flag

    Rat?....sell your shares please, love to buy more!
    MRNA ip is broad and holds much potential in the future of nucleic acid therapies.

  • Reply to

    New SMARTICLES (non-exclusive) license deal

    by btimnextmicrosoft Dec 18, 2014 11:28 AM
    btimnextmicrosoft btimnextmicrosoft Dec 18, 2014 2:41 PM Flag

    One more thought...since SMARTICLES is so widely used in clinical trials I suspect at least a $4 buyout if positive trials result. Don't you think one big pharma will pay huge bucks to exclusively own this ip??

  • Reply to

    check the largest holders of BTX

    by my_honest_opinion Dec 18, 2014 9:45 AM
    btimnextmicrosoft btimnextmicrosoft Dec 18, 2014 2:30 PM Flag

    BlackRock heavily invested too.

  • Reply to

    New SMARTICLES (non-exclusive) license deal

    by btimnextmicrosoft Dec 18, 2014 11:28 AM
    btimnextmicrosoft btimnextmicrosoft Dec 18, 2014 11:28 AM Flag

    Like this!:
    Michael French, president and CEO of Marina Biotech. "In addition, I believe it is also the most widely used delivery technology in human clinical studies for the development of nucleic acid therapeutics

  • btimnextmicrosoft by btimnextmicrosoft Dec 18, 2014 11:28 AM Flag

    BOTHELL, WA and SAN DIEGO, CA--(Marketwired - Dec 18, 2014) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and

    commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.

    "MiNA is focused on rapidly translating the benefits of saRNA therapeutics into the clinic," said Robert Habib, CEO of MiNA Therapeutics. "SMARTICLES have demonstrated highly efficient delivery of saRNAs to the liver and solid tumors along with a strong clinical track record and robust manufacturing. The formulation of saRNAs with SMARTICLES both accelerates and de-risks the development of MiNA's technology platform."

    "SMARTICLES is the most widely licensed delivery technology in the nucleic acid therapeutics sector now licensed to deliver single-stranded DNA oligonucleotides, double-stranded microRNA mimics and both single and double-stranded small activating RNA," stated J. Michael French, president and CEO of Marina Biotech. "In addition, I believe it is also the most widely used delivery technology in human clinical studies for the development of nucleic acid therapeutics. We are excited to be partnered with the pioneer in RNA activation therapeutics and...

  • Reply to

    Accumulated today because...

    by btimnextmicrosoft Dec 17, 2014 1:26 PM
    btimnextmicrosoft btimnextmicrosoft Dec 17, 2014 3:29 PM Flag

    Looking forward to next years results, btw I still think BTX and MRNA will collaborate on nano-peptide tumor targeting together sometime in 2015.

  • btimnextmicrosoft by btimnextmicrosoft Dec 17, 2014 1:26 PM Flag

    When positive Smarticle results come in big pharma will be fighting to buy us up. The key here is 'delivery', currently very few known ways to deliver RNAI/cells/drugs within the body......and MRNA has patented two
    delivery methods!

  • btimnextmicrosoft btimnextmicrosoft Dec 17, 2014 12:20 PM Flag

    GE Healthcare and Cellular Dynamics International Agree to Sublicense for Cellular Assay Patents
    Chalfont St. Giles, UK and MADISON, WIS, USA – 18 December 2012 – GE Healthcare Life Sciences, a business unit of GE Healthcare (NYSE: GE) and Cellular Dynamics International (CDI), a leading commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, announced today that GE Healthcare has licensed CDI to develop, manufacture and sell cellular assays and models derived from induced pluripotent stem (iPS) cells for use in drug discovery and toxicity screening. The agreement follows the recent announcement that GE Healthcare has expanded its license with Geron to obtain exclusive global rights to Geron’s intellectual property and know-how for the development and sale of cellular assays derived from iPS cells. Financial terms were not disclosed.

  • Any thoughts?

  • btimnextmicrosoft by btimnextmicrosoft Dec 16, 2014 2:59 PM Flag

    BTX and GE just struck a deal that seems identical to ICELLs 2012 deal using ips cells. Any thoughts?

  • btimnextmicrosoft btimnextmicrosoft Dec 16, 2014 2:55 PM Flag

    News from 2012, GE strikes deal with our top competitor Cellular Dynamics for drug testing/discovery using ips cells. Seems to me yesterday's BTX/GE deal tops this in that BTX acquires rights to use The GE/Geron ip left out in the BTX acquisition of Geron. And again GE goes with BTX and the hESC Gold Standard.
    2012:

  • Reply to

    Hi-Tech bigwigs added to LifeMap

    by ipstissueface Oct 1, 2014 1:56 PM
    btimnextmicrosoft btimnextmicrosoft Dec 16, 2014 2:20 PM Flag

    Bump...just a reminder: LifeMap Medical app, might be announcing release of 2.0 VERY soon.

  • Actually Dr West said something about not having enough time to include but we all know it's top secret and they want to keep it under wraps. Good news is that it will make a soft launch within a couple of weeks.

  • Reply to

    BTX summary

    by baltbearfinance Nov 10, 2014 6:54 PM
    btimnextmicrosoft btimnextmicrosoft Dec 15, 2014 11:29 PM Flag

    GE added to partner list.

  • btimnextmicrosoft by btimnextmicrosoft Dec 15, 2014 5:05 PM Flag

    PanC-DX(cancer diagnostic products) peer review papers were submitted and there will be presentations this Spring at the annual cancer screening conference. Block buster products on the market possibly within one year!

  • Reply to

    BTX massive UP move Coming !

    by wallstreetguys Dec 15, 2014 2:02 PM
    btimnextmicrosoft btimnextmicrosoft Dec 15, 2014 2:09 PM Flag

    Still under the radar. Cramer and CNBC guys will be talking about us next year.......after they buy up shares.

  • BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaboration with investigators in the Department of Pathology, Division of Cytopathology, at a leading medical institution with an international reputation for excellence and discovery. Initial results of the study have been submitted for presentation at a large upcoming cancer society meeting; eventual publication of the final results in a peer-reviewed clinical journal is also anticipated.

    The goal of this clinical study was to assess the performance of OncoCyte’s proprietary diagnostic technology in detecting the most common type of bladder cancer; namely, urothelial carcinoma (UC) (previously designated transitional cell carcinoma). Study investigators collected urine samples from patients undergoing urine cytology for the diagnosis of either primary or recurrent bladder cancer. Patient urine samples were assessed microscopically for the presence of cancer cells using the current standard-of-care method of cytopathology; in parallel, OncoCyte scientists analyzed the remaining portion of the urine samples for gene expression, including expression of OncoCyte’s proprietary PanC-Dx™ markers. In some cases, the quality of the residual urine sample provided to OncoCyte did not allow for a valid analysis; in these cases additional replacement samples will be provided. A statistical analysis was performed and a panel of markers that discriminates UC from non-cancerous conditions was identified. The ability of the markers tested in the studies to determine the absence, presence, or progression of UC in patients will determine the specific nature of the bladder cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue.

    “There is a large and growing need for more sensitive, cost

SVFC
0.00020.0000(0.00%)Jan 27 2:49 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.